Prevention of meningococcal disease

Fetal and Pediatric Pathology

Volumn 25, Issue 6, 2006, Pages 311-319

  Woodard, Jennifer L ^a   Berman, David M ^a,b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b All Children's Hospital ^*  (United States)

Author keywords

Menactra; Meningitis; Meningococcal Vaccine; Meningococcemia; Meningococcus; Neisseria meningitidis

Indexed keywords

CEFOTAXIME; CEFTRIAXONE; MENINGOCOCCUS VACCINE; PENICILLIN G; PNEUMOCOCCUS VACCINE; POLYSACCHARIDE VACCINE;

ANTIBIOTIC RESISTANCE; CELLULAR IMMUNITY; CHILDHOOD MORTALITY; CLINICAL FEATURE; CLINICAL PRACTICE; DIAGNOSTIC PROCEDURE; DOSE RESPONSE; FOOD AND DRUG ADMINISTRATION; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNOGENICITY; INCIDENCE; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; NEWBORN MORBIDITY; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RISK FACTOR; SURVIVOR; TREATMENT RESPONSE;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; HUMANS; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS;

EID: 34548402470     PISSN: 15513815     EISSN: 15513823     Source Type: Journal    
DOI: 10.1080/15513810701209538     Document Type: Review

References (23)

1. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Prevention and control of meningococcal disease. MMWR 54: RR-7, 2005.
2. Lepow ML, Hughes PA. Meningococcal immunology. Immunol Allergy Clinics N Am 23:769-786, 2003.
3. Gaur S, Malhotra A, Whitley-Williams P. Rates of Neisseria meningitidis increasing in the young. Ped Ann 33(9):590-595, 2004.
4. Neisseria meningitides. In Principles and Practice of Pediatric Infectious Diseases, 2nd ed. Long S, ed. New York: Churchill Livingstone, 748-754, 2003.
5. Emonts M, Hazlezet JA, deGroot R, Hermans PWM. Host genetic determinants of Neisseria meningitidis infections. Lancet Infect Dis 3:565-577, 2003.
6. Lepow ML, Goldschneider I, Gold R, Randolph M, Gotschlich E. Persistence of antibody following immunization of children with groups A and C meningococal polysaccharide vaccines. Pediatrics 60:673-880, 1977.
7. Artenstein MS. Meningococcal infections 5: Duration of polysaccharide-vaccine-induced antibody. Bull World Health Org 45:291-293, 1971.
8. Kayhty H, Karanko V, Peltola H, Sarna S, Makela, PH. Serum antibodies to capsular polysaccharide vaccine of group A Neisseria meningitidis followed for three years in infants and children. J Infect Dis 142:861-868, 1980.
9. Zangwill KM, Stout RW, Carlone GM, et al. Duration of antibody response after meningococcal polysaccharide vaccination in U.S. air force personnel. J Infect Dis 169:847-852, 1994.
10. Miller E, Apicella M. T-cell modulation of the murine antibody response to Neisseria meningitidis group A capsular polysaccharide. Infect Immun 56:259-266, 1988.
11. Taylor C, Bright R. T-cell modulation of the antibody response to bacterial polysaccharide antigens. Infect Immun 57:180-185, 1988.
12. Danzig L. Meningococcal vaccines. Ped Infect Dis J 23:S285-292, 2004.
13. Harrison L, Dwyer D, Maples C, Billman L. Risk of meningococcal infection in college students. JAMA 281:1906-1910, 1999.
14. Miller E, Salisbury D, Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the U.K. - a success story. Vaccine 20:S58-67, 2001.
15. Ramsay M, Andrews N, Trotter C, Kaczmarski E, Miller E. Herd immunity from meningococcal serogroup C conjugate vaccine in england: Database analysis. Bri Med J 326:365-366, 2003.
16. Maiden M, Stuart J, and the U.K. Meningococcal carriage group. Carriage of serogroup C meningococci 1 year after meningococcal serogroup C conjugate polysaccharide vaccination. Lancet 359:1829-1831, 2002.
17. Trotter C, Andrews N, Kaczmarski E, Miller E, Ramsay M. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 364:365-367, 2004.
18. Borrow R, Goldblatt D, Andrews N, et al. Antibody persistence and immunological memory at age 4 years after meningococcal group C conjugate vaccination in children in the United Kingdom. J Infect Dis. 186:1353-1357, 2002.
19. Keyserling H, Papa T, Koranyi K, et al. Safety, immunogenicity, and immune memory of a novel meningococcal (Groups A, C, Y, and W-135) polysaccharie diptheria conjugate vaccine (MCV-4) in healthy adolescents. Arch Ped Adol Med. 159:907-913, 2005.
20. Healy M, Baker C. The future of meningococcal vaccines. Ped Infect Dis J 24:175-176, 2005.
21. Guillain-Barré syndrome among recipients of Menactra® meningococcal conjugate vaccine-United States, June-July 2005. MMWR 54:1023-1025, 2005.
22. Update: Guillain-Barré syndrome among recipients of Mencactra® meningococcal conjugate vaccine-United States October 2005-February 2006. MMWR 55:364-367, 2006.
23. Mitka M. New vaccine should ease meningitis fears. JAMA 293:1433-1434, 2005.